ProfileGDS5678 / 1418237_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 89% 89% 89% 91% 81% 81% 79% 80% 92% 94% 92% 94% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0871890
GSM967853U87-EV human glioblastoma xenograft - Control 27.0260989
GSM967854U87-EV human glioblastoma xenograft - Control 37.1460989
GSM967855U87-EV human glioblastoma xenograft - Control 47.2343289
GSM967856U87-EV human glioblastoma xenograft - Control 57.5850891
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6577881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6276981
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5471379
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6179380
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7054992
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.0587994
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6096692
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0573294
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6838192